Financial Performance - HBC recorded total operating revenues of NOK 72.2 million in Q4 2025, an increase from NOK 64.9 million in Q4 2024. Full year 2025 total operating revenues amounted to NOK 256.3 million compared to NOK 265.5 million in 2024 [1] - EBITDA for Q4 2025 was negative NOK 26.5 million, slightly worse than negative NOK 26.1 million in Q4 2024. For the full year 2025, EBITDA was negative NOK 72.9 million compared to negative NOK 65.3 million in 2024 [2] - Cash and cash equivalents increased by NOK 1.6 million during Q4 2025, ending at NOK 67.1 million as of December 31, 2025, with total liquidity reaching NOK 77.5 million [3] Product and Market Development - Human Nutrition B2B revenues increased by 300% year-on-year, driven by strong demand for ProGo® and CalGo®, along with a solid sales start for NT-II™ [6] - Expanded regulatory access achieved with ingredient approvals in Australia and South Korea, facilitating entry into large VMS and functional food markets [6] - Pet Nutrition B2B volumes and revenues improved, supported by increased customer engagement and trade-show activity [6] Research and Development - Significant R&D milestones achieved during Q4, including peer-review publication of the CalGo® bone health study and IRB approval for a clinical NT-II™ joint health study [6] - HBC has identified unique health benefits through scientific evidence, leading to important academic partnerships and the granting of several patents [5] Corporate Actions - HBC raised NOK 158 million in a private placement and sold a stake in AecorBio Inc. for USD 5 million during Q4, with transactions expected to finalize in Q1 2026 to support growth and R&D [6] - HBC spun out a biotech-focused company, HBC Immunology (HBCI), which has raised external finance for its lead program in prostate cancer [7]

Core Viewpoint - Hofseth BioCare ASA has decided to cancel its Subsequent Offering due to delays in the completion of a Private Placement and current share price levels, resulting in refunds for subscribers [4]. Group 1: Subsequent Offering - The Company planned a Subsequent Offering with gross proceeds of up to approximately NOK 30,000,000 through the issuance of up to 16,666,666 new ordinary shares at a subscription price of NOK 1.80 per share [2]. - The Board of Directors has resolved to cancel the Subsequent Offering, and all subscription amounts for Offer Shares will be refunded to the subscribers [4]. - Subscribers wishing to maintain their subscription must contact the Company by 16.30 (CET) on 18 December 2025, or their subscription will be cancelled [4]. Group 2: Private Placement - The Company is awaiting the receipt of all share deposits related to the Private Placement, which is expected to be completed shortly [3]. - The Private Placement has already generated gross proceeds of approximately NOK 158 million [2].

Group 1 - Christoph Baldegger, a primary insider and member of the Board of Directors at Hofseth BioCare ASA, has subscribed for 368,320 Offer shares in the Subsequent Offering [1] - After the share capital registration, Mr. Baldegger will hold a total of 3,616,296 shares in Hofseth BioCare ASA, representing approximately 0.92% of the total outstanding A-shares with voting rights [1] - This information is disclosed in accordance with the Market Abuse Regulation EU 596/2014 and the Norwegian Securities Trading Act [1]

Core Viewpoint - Hofseth BioCare ASA is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30,000,000 through the issuance of up to 16,666,666 new ordinary shares at a subscription price of NOK 1.80 per share [2]. Group 1: Offering Details - The Subsequent Offering is directed towards shareholders as of 24 October 2025, with certain exclusions for those who participated in a prior private placement and shareholders in jurisdictions where the offering is unlawful [3]. - The application period for the Subsequent Offering ended on 20 November 2025, with applications received for 1,215,560 Offer Shares [4]. - The Board has allocated all 1,215,560 Offer Shares to Eligible Shareholders, and allocation letters will be sent to subscribers shortly [5]. Group 2: Share Capital Increase - A general meeting held on 20 November 2025 authorized the Board to increase the Company's share capital by up to NOK 166,666.66, pending registration with the Norwegian Register of Business Enterprises [6]. - Completion of the Subsequent Offering is contingent upon the registration of the share capital increase, receipt of payment for all subscribed Offer Shares, and valid resolutions by the Board [7].

Company Overview - Hofseth BioCare ASA (HBC) is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1] - The company upcycles by converting side streams of the salmon industry into health-improving ingredients for humans and pets [1] Product Offerings - HBC's key products include ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, and CalGo® / NT-II® salmon bone powder [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality [3] - OmeGo® provides immune health benefits and aids recovery from viral infections [3] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [3] Scientific Research and Development - HBC emphasizes scientific evidence, resulting in academic partnerships and unique health benefit discoveries [3] - The company has secured patents for its findings and has identified potential therapeutics, leading to the establishment of HBC Immunology (HBCI) [3] - HBCI has raised external finance for its lead program targeting prostate cancer and ovarian cancer, along with a molecule aimed at asthma treatment [3] Corporate Structure and Location - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Insights - Hofseth BioCare ASA (HBC) held an Extraordinary General Meeting on November 20, 2025, where all proposals were approved as per the notice issued on October 30, 2025 [1] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability, optimal utilization of natural resources, and full traceability [1] - The company upcycles byproducts from the salmon industry, converting waste into health-improving ingredients for humans and pets [1] Product Offerings - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality, while OmeGo® supports immune health and recovery from viral infections [3] - CalGo® promotes bone and joint health, aiding healthy aging and active lifestyles [3] Scientific and Academic Partnerships - HBC emphasizes scientific evidence, resulting in academic partnerships and the identification of unique health benefits [3] - The company has secured patents for its discoveries and has spun out a biotech-focused entity, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [3] Corporate Structure - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Points - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering of up to 16,666,666 new shares at a subscription price of NOK 1.80 per share [2][5] - The Subscription Period for the Offering will expire on 20 November 2025 at 16:30 hours (CET) [3] - Unused subscription rights will lapse without compensation after the Subscription Period [3] Offering Details - The subscription forms must be correctly completed and received by DNB Carnegie before the expiry of the Subscription Period [4] - The Company has published a national prospectus in accordance with the Norwegian Securities Trading Act, which is available on its website [5] Contact Information - For further inquiries, Jon Olav Ødegård, CEO at HBC, can be contacted via phone or email [6]

Core Insights - Hofseth BioCare (HBC) has announced a strategic partnership with Metabolic Elite to develop a premium range of performance nutrition products for elite athletes, leveraging HBC's bioactive ingredients and Metabolic Elite's advanced formulations [1][2] Company Overview - HBC is a Norwegian company focused on sustainable marine-based nutrition, utilizing side streams from the salmon industry to create health-improving ingredients such as ProGo®, OmeGo®, and CalGo® [4][5] - The company emphasizes scientific evidence and has established academic partnerships to validate the health benefits of its products, including improved iron metabolism and immune health [5][6] Product Development - The collaboration aims to enhance athletic performance through improved recovery, endurance, and metabolic efficiency, while also addressing individual metabolic needs with targeted nutrition [2][8] - HBC's ingredients are clinically proven to support metabolic health, muscle protection, energy, and weight management, making them suitable for high performers and active individuals [2][5] Leadership and Expertise - Jim LaValle, a recognized expert in precision health and the Chief Science Officer of Metabolic Elite, will guide the product formulations, bringing over 40 years of experience in metabolic optimization [3][9] - LaValle's background includes developing personalized health programs and working with various professional sports teams to enhance performance and resilience [10][12] Innovation and Patents - HBC has secured several patents for its discoveries, leading to the establishment of HBC Immunology, which focuses on potential therapeutics for conditions like prostate cancer and asthma [6]

Core Insights - HBC reported total operating revenues of NOK 54.9 million in Q3 2025, down from NOK 67.9 million in the same period last year, attributed to lower commodity prices and a weaker U.S. dollar [1] - The company experienced an EBITDA of NOK -21.1 million, with operational EBITDA at NOK -12.9 million, excluding non-recurring costs [2] - Cash and cash equivalents decreased by NOK 2.6 million, ending at NOK 65.5 million, while total liquidity, including credit facilities, was NOK 67.0 million at quarter-end [3] Financial Performance - The Midsund plant processed 5,288 tonnes of raw material, marking the highest quarterly volume in HBC's history, with a gross margin improvement to 35% from 28% [8] - Human Nutrition B2B sales surged by 200% year-over-year, driven by products like OmeGo® and ProGo®, which also won the NutraIngredients-USA "Healthy Aging" Award [8] - Consumer & Pet Health (B2C) revenues grew by 30%, supported by new European listings and product extensions [8] Product Development and Innovation - HBC focuses on sustainability and optimal utilization of natural resources, converting salmon industry by-products into health-improving ingredients [4] - Key products include ProGo®, OmeGo®, and CalGo® / NT-II®, which have shown various health benefits, including improved iron metabolism and bone health [5][6] - HBC has established academic partnerships and secured patents for its discoveries, leading to the formation of HBC Immunology, which is developing therapeutics for prostate and ovarian cancer [6] Market Position and Strategy - HBC is listed on Oslo Børs under the ticker "HBC" and emphasizes scientific evidence in its product development [7] - The company aims to enhance its equity and liquidity position following a successful private placement in October 2025 [3]

Core Points - Hofseth BioCare ASA (HBC) is conducting a private placement of new shares, with the completion of tranche 2 (T2 Offer Shares) contingent upon an extraordinary general meeting (EGM) [1] - The EGM is scheduled for 20 November 2025, and the company has secured voting commitments from shareholders to meet the majority requirement for approval [2] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, converting by-products from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [4] Scientific and Health Benefits - HBC emphasizes scientific evidence in its product development, leading to partnerships and the identification of health benefits, including improved iron metabolism and immune health [5] - The company has secured several patents for its discoveries and has established a biotech subsidiary, AecorBio Inc., focusing on therapeutics for prostate and ovarian cancer, as well as asthma [6] Market Presence - HBC is listed on the Oslo Stock Exchange under the ticker "HBC" [7]